The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Live Attenuated Vaccine for Chickenpox Market Research Report 2025

Global Live Attenuated Vaccine for Chickenpox Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1727819

No of Pages : 96

Ask Your Query

Synopsis
Highlights
The global Live Attenuated Vaccine for Chickenpox market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
The major global manufacturers of Live Attenuated Vaccine for Chickenpox include GSK, Sanofi Pasteur, Merck & Co lnc, BCHT, Green Cross, Keygen, Biken, Chengdu Institute of Biological Products Co., Ltd and Changchun Qijian Biological Products Co., Ltd, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Child, which accounted for % of the global market of Live Attenuated Vaccine for Chickenpox in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Live Attenuated Vaccine for Chickenpox, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Vaccine for Chickenpox.
The Live Attenuated Vaccine for Chickenpox market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Live Attenuated Vaccine for Chickenpox market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Live Attenuated Vaccine for Chickenpox manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Some of the prominent players reviewed in the research report include:

  • GSK
  • Sanofi Pasteur
  • Merck & Co lnc
  • BCHT
  • Green Cross
  • Keygen
  • Biken
  • Chengdu Institute of Biological Products Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd
  • Kexing (Dalian) Vaccine Technology Co., Ltd
  • Beijing Institute of Biological Products Co., Ltd
  • Changchun Baike Biotechnology Co., Ltd
  • Shanghai Rongsheng Biopharmaceutical Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd

Product Type Insights
Global markets are presented by Live Attenuated Vaccine for Chickenpox type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Live Attenuated Vaccine for Chickenpox are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Live Attenuated Vaccine for Chickenpox segment by Type

  • Child
  • Adult

Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Live Attenuated Vaccine for Chickenpox market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Live Attenuated Vaccine for Chickenpox market.

Live Attenuated Vaccine for Chickenpox segment by Application

  • Hospital
  • Clinic

Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Live Attenuated Vaccine for Chickenpox market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

  • This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccine for Chickenpox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
  • This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccine for Chickenpox and provides them with information on key market drivers, restraints, challenges, and opportunities.
  • This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
  • This report stays updated with novel technology integration, features, and the latest developments in the market
  • This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Live Attenuated Vaccine for Chickenpox industry.
  • This report helps stakeholders to gain insights into which regions to target globally
  • This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccine for Chickenpox.
  • This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Live Attenuated Vaccine for Chickenpox manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Live Attenuated Vaccine for Chickenpox in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.

Index

1 Live Attenuated Vaccine for Chickenpox Market Overview
1.1 Product Overview and Scope of Live Attenuated Vaccine for Chickenpox
1.2 Live Attenuated Vaccine for Chickenpox Segment by Type
1.2.1 Global Live Attenuated Vaccine for Chickenpox Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Child
1.2.3 Adult
1.3 Live Attenuated Vaccine for Chickenpox Segment by Application
1.3.1 Global Live Attenuated Vaccine for Chickenpox Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Live Attenuated Vaccine for Chickenpox Market Size Estimates and Forecasts
1.4.1 Global Live Attenuated Vaccine for Chickenpox Revenue 2017-2028
1.4.2 Global Live Attenuated Vaccine for Chickenpox Sales 2017-2028
1.4.3 Live Attenuated Vaccine for Chickenpox Market Size by Region: 2017 Versus 2021 Versus 2028
2 Live Attenuated Vaccine for Chickenpox Market Competition by Manufacturers
2.1 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Manufacturers (2017-2022)
2.2 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Live Attenuated Vaccine for Chickenpox Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Live Attenuated Vaccine for Chickenpox Manufacturing Sites, Area Served, Product Type
2.5 Live Attenuated Vaccine for Chickenpox Market Competitive Situation and Trends
2.5.1 Live Attenuated Vaccine for Chickenpox Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Live Attenuated Vaccine for Chickenpox Players Market Share by Revenue
2.5.3 Global Live Attenuated Vaccine for Chickenpox Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Live Attenuated Vaccine for Chickenpox Retrospective Market Scenario by Region
3.1 Global Live Attenuated Vaccine for Chickenpox Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Live Attenuated Vaccine for Chickenpox Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
3.3.1 North America Live Attenuated Vaccine for Chickenpox Sales by Country
3.3.2 North America Live Attenuated Vaccine for Chickenpox Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
3.4.1 Europe Live Attenuated Vaccine for Chickenpox Sales by Country
3.4.2 Europe Live Attenuated Vaccine for Chickenpox Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Region
3.5.1 Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Region
3.5.2 Asia Pacific Live Attenuated Vaccine for Chickenpox Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
3.6.1 Latin America Live Attenuated Vaccine for Chickenpox Sales by Country
3.6.2 Latin America Live Attenuated Vaccine for Chickenpox Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
3.7.1 Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country
3.7.2 Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Live Attenuated Vaccine for Chickenpox Historic Market Analysis by Type
4.1 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2017-2022)
4.2 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2017-2022)
4.3 Global Live Attenuated Vaccine for Chickenpox Price by Type (2017-2022)
5 Global Live Attenuated Vaccine for Chickenpox Historic Market Analysis by Application
5.1 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2017-2022)
5.2 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2017-2022)
5.3 Global Live Attenuated Vaccine for Chickenpox Price by Application (2017-2022)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.1.4 GSK Live Attenuated Vaccine for Chickenpox Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Sanofi Pasteur
6.2.1 Sanofi Pasteur Corporation Information
6.2.2 Sanofi Pasteur Description and Business Overview
6.2.3 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio
6.2.5 Sanofi Pasteur Recent Developments/Updates
6.3 Merck & Co lnc
6.3.1 Merck & Co lnc Corporation Information
6.3.2 Merck & Co lnc Description and Business Overview
6.3.3 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio
6.3.5 Merck & Co lnc Recent Developments/Updates
6.4 BCHT
6.4.1 BCHT Corporation Information
6.4.2 BCHT Description and Business Overview
6.4.3 BCHT Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.4.4 BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio
6.4.5 BCHT Recent Developments/Updates
6.5 Green Cross
6.5.1 Green Cross Corporation Information
6.5.2 Green Cross Description and Business Overview
6.5.3 Green Cross Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio
6.5.5 Green Cross Recent Developments/Updates
6.6 Keygen
6.6.1 Keygen Corporation Information
6.6.2 Keygen Description and Business Overview
6.6.3 Keygen Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio
6.6.5 Keygen Recent Developments/Updates
6.7 Biken
6.6.1 Biken Corporation Information
6.6.2 Biken Description and Business Overview
6.6.3 Biken Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Biken Live Attenuated Vaccine for Chickenpox Product Portfolio
6.7.5 Biken Recent Developments/Updates
6.8 Chengdu Institute of Biological Products Co., Ltd
6.8.1 Chengdu Institute of Biological Products Co., Ltd Corporation Information
6.8.2 Chengdu Institute of Biological Products Co., Ltd Description and Business Overview
6.8.3 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
6.8.5 Chengdu Institute of Biological Products Co., Ltd Recent Developments/Updates
6.9 Changchun Qijian Biological Products Co., Ltd
6.9.1 Changchun Qijian Biological Products Co., Ltd Corporation Information
6.9.2 Changchun Qijian Biological Products Co., Ltd Description and Business Overview
6.9.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
6.9.5 Changchun Qijian Biological Products Co., Ltd Recent Developments/Updates
6.10 Kexing (Dalian) Vaccine Technology Co., Ltd
6.10.1 Kexing (Dalian) Vaccine Technology Co., Ltd Corporation Information
6.10.2 Kexing (Dalian) Vaccine Technology Co., Ltd Description and Business Overview
6.10.3 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
6.10.5 Kexing (Dalian) Vaccine Technology Co., Ltd Recent Developments/Updates
6.11 Beijing Institute of Biological Products Co., Ltd
6.11.1 Beijing Institute of Biological Products Co., Ltd Corporation Information
6.11.2 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Description and Business Overview
6.11.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
6.11.5 Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
6.12 Changchun Baike Biotechnology Co., Ltd
6.12.1 Changchun Baike Biotechnology Co., Ltd Corporation Information
6.12.2 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Description and Business Overview
6.12.3 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
6.12.5 Changchun Baike Biotechnology Co., Ltd Recent Developments/Updates
6.13 Shanghai Rongsheng Biopharmaceutical Co., Ltd
6.13.1 Shanghai Rongsheng Biopharmaceutical Co., Ltd Corporation Information
6.13.2 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Description and Business Overview
6.13.3 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
6.13.5 Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Developments/Updates
6.14 Shanghai Institute of Biological Products Co., Ltd
6.14.1 Shanghai Institute of Biological Products Co., Ltd Corporation Information
6.14.2 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Description and Business Overview
6.14.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
6.14.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
7 Live Attenuated Vaccine for Chickenpox Manufacturing Cost Analysis
7.1 Live Attenuated Vaccine for Chickenpox Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Live Attenuated Vaccine for Chickenpox
7.4 Live Attenuated Vaccine for Chickenpox Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Live Attenuated Vaccine for Chickenpox Distributors List
8.3 Live Attenuated Vaccine for Chickenpox Customers
9 Live Attenuated Vaccine for Chickenpox Market Dynamics
9.1 Live Attenuated Vaccine for Chickenpox Industry Trends
9.2 Live Attenuated Vaccine for Chickenpox Market Drivers
9.3 Live Attenuated Vaccine for Chickenpox Market Challenges
9.4 Live Attenuated Vaccine for Chickenpox Market Restraints
10 Global Market Forecast
10.1 Live Attenuated Vaccine for Chickenpox Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Live Attenuated Vaccine for Chickenpox by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Live Attenuated Vaccine for Chickenpox by Type (2023-2028)
10.2 Live Attenuated Vaccine for Chickenpox Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Live Attenuated Vaccine for Chickenpox by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Live Attenuated Vaccine for Chickenpox by Application (2023-2028)
10.3 Live Attenuated Vaccine for Chickenpox Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Live Attenuated Vaccine for Chickenpox by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Live Attenuated Vaccine for Chickenpox by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Live Attenuated Vaccine for Chickenpox Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Live Attenuated Vaccine for Chickenpox Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Live Attenuated Vaccine for Chickenpox Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Live Attenuated Vaccine for Chickenpox Market Competitive Situation by Manufacturers in 2021
Table 5. Global Live Attenuated Vaccine for Chickenpox Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Live Attenuated Vaccine for Chickenpox Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Live Attenuated Vaccine for Chickenpox Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Live Attenuated Vaccine for Chickenpox Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Live Attenuated Vaccine for Chickenpox Manufacturing Sites and Area Served
Table 11. Manufacturers Live Attenuated Vaccine for Chickenpox Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Live Attenuated Vaccine for Chickenpox by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Live Attenuated Vaccine for Chickenpox as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Live Attenuated Vaccine for Chickenpox Sales by Region (2017-2022) & (K Units)
Table 16. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2017-2022)
Table 17. Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2017-2022)
Table 19. North America Live Attenuated Vaccine for Chickenpox Sales by Country (2017-2022) & (K Units)
Table 20. North America Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2017-2022)
Table 21. North America Live Attenuated Vaccine for Chickenpox Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Live Attenuated Vaccine for Chickenpox Revenue Market Share by Country (2017-2022)
Table 23. Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2017-2022) & (K Units)
Table 24. Europe Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2017-2022)
Table 25. Europe Live Attenuated Vaccine for Chickenpox Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Live Attenuated Vaccine for Chickenpox Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Live Attenuated Vaccine for Chickenpox Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2017-2022)
Table 31. Latin America Live Attenuated Vaccine for Chickenpox Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2017-2022)
Table 33. Latin America Live Attenuated Vaccine for Chickenpox Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Live Attenuated Vaccine for Chickenpox Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue Market Share by Country (2017-2022)
Table 39. Global Live Attenuated Vaccine for Chickenpox Sales by Type (2017-2022) & (K Units)
Table 40. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2017-2022)
Table 41. Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Live Attenuated Vaccine for Chickenpox Revenue Share by Type (2017-2022)
Table 43. Global Live Attenuated Vaccine for Chickenpox Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Live Attenuated Vaccine for Chickenpox Sales (K Units) by Application (2017-2022)
Table 45. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2017-2022)
Table 46. Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Live Attenuated Vaccine for Chickenpox Revenue Share by Application (2017-2022)
Table 48. Global Live Attenuated Vaccine for Chickenpox Price by Application (2017-2022) & (US$/Unit)
Table 49. GSK Corporation Information
Table 50. GSK Description and Business Overview
Table 51. GSK Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. GSK Live Attenuated Vaccine for Chickenpox Product
Table 53. GSK Recent Developments/Updates
Table 54. Sanofi Pasteur Corporation Information
Table 55. Sanofi Pasteur Description and Business Overview
Table 56. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product
Table 58. Sanofi Pasteur Recent Developments/Updates
Table 59. Merck & Co lnc Corporation Information
Table 60. Merck & Co lnc Description and Business Overview
Table 61. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product
Table 63. Merck & Co lnc Recent Developments/Updates
Table 64. BCHT Corporation Information
Table 65. BCHT Description and Business Overview
Table 66. BCHT Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. BCHT Live Attenuated Vaccine for Chickenpox Product
Table 68. BCHT Recent Developments/Updates
Table 69. Green Cross Corporation Information
Table 70. Green Cross Description and Business Overview
Table 71. Green Cross Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Green Cross Live Attenuated Vaccine for Chickenpox Product
Table 73. Green Cross Recent Developments/Updates
Table 74. Keygen Corporation Information
Table 75. Keygen Description and Business Overview
Table 76. Keygen Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Keygen Live Attenuated Vaccine for Chickenpox Product
Table 78. Keygen Recent Developments/Updates
Table 79. Biken Corporation Information
Table 80. Biken Description and Business Overview
Table 81. Biken Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Biken Live Attenuated Vaccine for Chickenpox Product
Table 83. Biken Recent Developments/Updates
Table 84. Chengdu Institute of Biological Products Co., Ltd Corporation Information
Table 85. Chengdu Institute of Biological Products Co., Ltd Description and Business Overview
Table 86. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product
Table 88. Chengdu Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 89. Changchun Qijian Biological Products Co., Ltd Corporation Information
Table 90. Changchun Qijian Biological Products Co., Ltd Description and Business Overview
Table 91. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product
Table 93. Changchun Qijian Biological Products Co., Ltd Recent Developments/Updates
Table 94. Kexing (Dalian) Vaccine Technology Co., Ltd Corporation Information
Table 95. Kexing (Dalian) Vaccine Technology Co., Ltd Description and Business Overview
Table 96. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product
Table 98. Kexing (Dalian) Vaccine Technology Co., Ltd Recent Developments/Updates
Table 99. Beijing Institute of Biological Products Co., Ltd Corporation Information
Table 100. Beijing Institute of Biological Products Co., Ltd Description and Business Overview
Table 101. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product
Table 103. Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 104. Changchun Baike Biotechnology Co., Ltd Corporation Information
Table 105. Changchun Baike Biotechnology Co., Ltd Description and Business Overview
Table 106. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product
Table 108. Changchun Baike Biotechnology Co., Ltd Recent Developments/Updates
Table 109. Shanghai Rongsheng Biopharmaceutical Co., Ltd Corporation Information
Table 110. Shanghai Rongsheng Biopharmaceutical Co., Ltd Description and Business Overview
Table 111. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product
Table 113. Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 114. Shanghai Institute of Biological Products Co., Ltd Corporation Information
Table 115. Shanghai Institute of Biological Products Co., Ltd Description and Business Overview
Table 116. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 117. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product
Table 118. Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 119. Production Base and Market Concentration Rate of Raw Material
Table 120. Key Suppliers of Raw Materials
Table 121. Live Attenuated Vaccine for Chickenpox Distributors List
Table 122. Live Attenuated Vaccine for Chickenpox Customers List
Table 123. Live Attenuated Vaccine for Chickenpox Market Trends
Table 124. Live Attenuated Vaccine for Chickenpox Market Drivers
Table 125. Live Attenuated Vaccine for Chickenpox Market Challenges
Table 126. Live Attenuated Vaccine for Chickenpox Market Restraints
Table 127. Global Live Attenuated Vaccine for Chickenpox Sales Forecast by Type (2023-2028) & (K Units)
Table 128. Global Live Attenuated Vaccine for Chickenpox Sales Market Share Forecast by Type (2023-2028)
Table 129. Global Live Attenuated Vaccine for Chickenpox Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 130. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share Forecast by Type (2023-2028)
Table 131. Global Live Attenuated Vaccine for Chickenpox Sales Forecast by Application (2023-2028) & (K Units)
Table 132. Global Live Attenuated Vaccine for Chickenpox Sales Market Share Forecast by Application (2023-2028)
Table 133. Global Live Attenuated Vaccine for Chickenpox Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 134. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share Forecast by Application (2023-2028)
Table 135. Global Live Attenuated Vaccine for Chickenpox Sales Forecast by Region (2023-2028) & (K Units)
Table 136. Global Live Attenuated Vaccine for Chickenpox Sales Market Share Forecast by Region (2023-2028)
Table 137. Global Live Attenuated Vaccine for Chickenpox Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 138. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share Forecast by Region (2023-2028)
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Live Attenuated Vaccine for Chickenpox
Figure 2. Global Live Attenuated Vaccine for Chickenpox Market Share by Type in 2021 & 2028
Figure 3. Child Product Picture
Figure 4. Adult Product Picture
Figure 5. Global Live Attenuated Vaccine for Chickenpox Market Share by Application in 2021 & 2028
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Global Live Attenuated Vaccine for Chickenpox Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Live Attenuated Vaccine for Chickenpox Market Size (2017-2028) & (US$ Million)
Figure 10. Global Live Attenuated Vaccine for Chickenpox Sales (2017-2028) & (K Units)
Figure 11. Live Attenuated Vaccine for Chickenpox Sales Share by Manufacturers in 2021
Figure 12. Global Live Attenuated Vaccine for Chickenpox Revenue Share by Manufacturers in 2021
Figure 13. The Global 5 and 10 Largest Live Attenuated Vaccine for Chickenpox Players: Market Share by Revenue in 2021
Figure 14. Live Attenuated Vaccine for Chickenpox Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 15. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2017-2022)
Figure 16. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region in 2021
Figure 17. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2017-2022)
Figure 18. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region in 2021
Figure 19. United States Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 20. Canada Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Germany Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. France Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. U.K. Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Italy Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Russia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. China Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Japan Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. South Korea Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. India Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Australia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Taiwan Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Indonesia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Thailand Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Malaysia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Mexico Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Brazil Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Argentina Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Colombia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Turkey Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Saudi Arabia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. UAE Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Sales Market Share of Live Attenuated Vaccine for Chickenpox by Type (2017-2022)
Figure 43. Manufacturing Cost Structure of Live Attenuated Vaccine for Chickenpox
Figure 44. Manufacturing Process Analysis of Live Attenuated Vaccine for Chickenpox
Figure 45. Live Attenuated Vaccine for Chickenpox Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock